Lorundrostat for hypertension

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 14 Jul 2023: Trial started, NCT05968430
  2. 1 Aug 2023: Trial registered, NCT05968430
  3. 22 Nov 2023: Trial started, NCT06153693
  4. 1 Dec 2023: Trial registered, NCT06153693

The trials

NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

State
Completed
Phase
Phase 2
People
285 taking part
Started
13 Mar 2023
Primary completion
15 Jan 2025
Arms
Dose 1, Dose 2
Results
None posted
  1. 13 Mar 2023: Trial started
  2. 15 Mar 2023: Trial registered
  3. 15 Jan 2025: Trial completed

NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

State
Under way
Phase
Phase 3
People
1,076 taking part
Started
14 Jul 2023
Primary completion
30 Dec 2025
Arms
Open-Label Arm, Optional Continuation Period
Results
None posted
  1. 14 Jul 2023: Trial started
  2. 1 Aug 2023: Trial registered

NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

State
Completed
Phase
Phase 3
People
1,083 taking part
Started
22 Nov 2023
Primary completion
10 Dec 2024
Arms
Dose 1, Dose 2
Results
None posted
  1. 22 Nov 2023: Trial started
  2. 1 Dec 2023: Trial registered
  3. 24 Jan 2025: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as lorundrostat Dose 1, lorundrostat Dose 2.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.